MDS
Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Advertisement
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain.
The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.
The researchers found a perfect correlation between the AI-based multiparametric flow cytometry score and the IPSS-M.
Discrepancies between the WHO and ICC classification systems for MDS can create inconsistencies in a clinical setting.
Through genomic profiling, researchers identified 18 MDS subtypes associated with clinical outcomes.
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
Patients who received oral HMAs had half the mean total of health care encounter days as those who received IV or SC HMAs.
A TP53 variant allele frequency threshold of 24% can inform MDS prognosis equally as well as TP53 allelic status.
The IPSS-M significantly improved MDS prognostic assessment, particularly for high-risk IPSS-R cases.
In patients with lower-risk MDS receiving luspatercept, electronic medical record alerts can help improve treatment dosing.
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.
Luspatercept yielded high rates of durable transfusion independence in heavily-pretreated, lower-risk MDS.
Luspatercept yielded greater rates of improvement in cell lineages for patients with transfusion-dependent MDS.
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
Enrolled patients had non-del(5q) relapsed or refractory disease and were ineligible for erythropoiesis-stimulating agents.
A retrospective study's regression analysis confirmed survival effect of cytarabine-based regimens and allogeneic HSCT.
Inherited thrombocytopenia is associated with risk for myelodysplastic syndromes and malignancies.
A shorter time to response was still observed in the azacitidine plus venetoclax cohort in this retrospective study.
In recent studies, optical genome mapping detected additional genetic aberrations in MDS compared to conventional techniques.
Most patients with MDS achieved an objective response, but limited clinical activity was observed across other blood cancers.
The two-year cumulative incidence of relapse was lower in those who achieved full donor chimerism than in those who didn’t.
“Blood Cancer Talks" hosts are joined by Dr. Stahl to discuss imetelstat and luspatercept treatment for lower-risk MDS.
An analysis of the PEGASUS and PRINCE clinical trials reported long-term efficacy of pegcetacoplan for patients with PNH.
Imetelstat led to significant improvement of red blood cell-transfusion independence rates in patients with lower-risk MDS.
Combination therapies involving PD-1 and CTLA-4 inhibitors exhibited promising activity and tolerability.
Treatment with luspatercept led to significantly less healthcare resource utilization compared with ESAs.
Dr. Raddi discusses his study on identifying predictors of response to ESA therapy in patients with lower-risk MDS.
Compared with epoetin alfa, luspatercept improved transfusion independence and hematological improvement in lower-risk MDS.
A study on this MDS subtype found that the allelic states of these mutations have implications for disease behavior.
The study compared outcomes after two conditioning types: myeloablative conditioning and reduced intensity conditioning.
There were no differences in OS among patients with NPM1-mutated myeloid neoplasms with varying bone marrow blasts.
Azacitidine plus quizartinib achieved a high ORR and a promising safety profile in patients with FLT3-Mutated MDS.
Two clinical experts offer detailed guidance on how to use iron chelation therapy in MDS care.
Multivariable analysis in a phase II study linked the supplements to an overall survival benefit in patients.
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
A high percentage of MSC-like cells at MDS diagnosis carries a significantly earlier conversion of the disease to AML.
Results from a new analysis reaffirm the initial findings of the global, phase III IMerge trial.
Researchers construct a single MDS classification system which integrates the two major international systems.
The study was a noninterventional based on data collected through November 2023.
Dr. Sockel from University Hospital Carl Gustav Carus Dresden discusses recent progress and new directions in MDS management.
Elias Jabbour, MD, gives MDS highlights from EHA 2024.
Compared with epoetin alfa, luspatercept more frequently yielded improvements in anemia measures in lower-risk MDS.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.